Chiara Foglieni

Dr. Chiara Foglieni

IRCCS Ospedale San Raffaele, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
FBFrancesco Broccolo
Francesco Broccolo
FDFrancesco Drago
Francesco Drago
ACAnna M. Careddu
Anna M. Careddu
CFChiara Foglieni
Chiara Foglieni
LTLaura Turbino
Laura Turbino
MMMauro S. Malnati
Mauro S. Malnati

1 July 1997 in Kidney International
Verified
Journal Article
Closed access
SASistiana Aiello
Sistiana Aiello
MNMarina Noris
Marina Noris
MTMarta Todeschini
Marta Todeschini
SZSergio Zappella
Sergio Zappella
CFChiara Foglieni
Chiara Foglieni
Giuseppe RemuzziGiuseppe Remuzzi
Giuseppe Remuzzi

1 March 2010 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
PDF file
SLSilvia Langheim
Silvia Langheim
LDLorella Dreas
Lorella Dreas
LVLorenzo Veschini
Lorenzo Veschini
FMFrancesco Maisano
Francesco Maisano
CFChiara Foglieni
Chiara Foglieni
GRGiacomo Ruotolo
Giacomo Ruotolo
The purpose of this study was to test the hypothesis that specific epicardial adipose tissue (EAT) proinflammatory adipokines might be implicated in acute coronary syndrome (ACS). We compared expression and protein secretion of several EAT adipokines of male ACS with those of matched stable coronary artery disease (CAD) patients and controls with angiographically normal coronary arteries. The effect of supernatant of cultured EAT on endothelial cell permeability in vitro was also evaluated in the three study groups. EAT of ACS patients showed significantly higher gene expression and protein secretion of resistin than patients with stable CAD. Interleukin-6, plasminogen activator inhibitor-1, and monocyte chemoattractant protein-1 genes were also significantly overexpressed in ACS compared with the control group but not when compared with stable CAD. Immunofluorescence of EAT sections revealed a significantly greater number of CD68+cells in ACS patients than stable CAD and control groups. The permeability of endothelial cells in vitro was significantly increased after exposure to supernatant of cultured EAT from ACS, but not control or stable CAD groups, and this effect was normalized by anti-resistin antiserum. We found that EAT of patients with ACS is characterized by increased expression and secretion of resistin and associated with increased in vitro endothelial cell permeability.

1 March 2001 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
CFChiara Foglieni
Chiara Foglieni
CMCesare Meoni
Cesare Meoni
ADAlberto M. Davalli
Alberto M. Davalli

1 May 2000 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
ABAlessandra Bragonzi
Alessandra Bragonzi
GDGianfranco Distefano
Gianfranco Distefano
LBLorraine D Buckberry
Lorraine D Buckberry
GAGiulia Acerbis
Giulia Acerbis
CFChiara Foglieni
Chiara Foglieni
LMLucia Monaco
Lucia Monaco

20 January 2004 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
EFElisabetta Ferrero
Elisabetta Ferrero
SSSilvia Scabini
Silvia Scabini
EMElena Magni
Elena Magni
CFChiara Foglieni
Chiara Foglieni
DBDaniela Belloni
Daniela Belloni
ACAngelo Corti
Angelo Corti
Elevated levels of circulating chromogranin A (CgA), a protein stored in the secretory granules of many neuroendocrine cells and neurons, have been detected in the blood of patients with neuroendocrine tumors or heart failure. The pathophysiological role of increased secretion of CgA is unknown. Using mice bearing subcutaneous tumors genetically engineered to secrete CgA in circulation, we have found that increased blood levels of this protein prevent vascular leakage induced by tumor necrosis factor‐α (TNF) in the liver venous system. Structure–activity studies, carried out with CgA fragments administered to normal mice, showed that an active site is located within residues 7–57 of CgA. Accordingly, an anti‐CgA antibody directed to residues 53–57 inhibited the effect of circulating CgA, either endogenously produced or exogenously administered, on liver vessels. Studies of the mechanism of action showed that CgA inhibits TNF‐induced VE‐cadherin down‐regulation and barrier alteration of cultured endothelial cells, in an indirect manner. Other effectors, such as thrombin and vascular endothelial growth factor were partially inhibited by CgA N‐terminal fragments in in vitro permeability assays. These findings suggest that circulating CgA could help regulate the endothelial barrier function and to protect vessels against TNF‐induced plasma leakage in pathological conditions characterized by increased production of TNF and CgA, such as cancer or heart failure.